Quiros Juan Jose Chacon Sells 33,925 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the completion of the sale, the director owned 1,223,579 shares of the company’s stock, valued at approximately $73,891,935.81. This trade represents a 2.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Establishment Labs Trading Up 2.4%

ESTA opened at $59.57 on Thursday. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $83.31. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The stock has a market capitalization of $1.75 billion, a PE ratio of -34.24 and a beta of 0.91. The firm’s fifty day moving average price is $69.34 and its 200 day moving average price is $61.78.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the business earned ($1.19) EPS. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ESTA. Mizuho boosted their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Citigroup reduced their target price on Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. BTIG Research lifted their target price on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen upgraded Establishment Labs from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, Needham & Company LLC upped their price target on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus target price of $86.86.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors have recently modified their holdings of ESTA. Kestra Advisory Services LLC bought a new position in Establishment Labs during the 4th quarter worth $47,000. Quarry LP acquired a new stake in Establishment Labs in the third quarter worth $34,000. State of Wyoming bought a new stake in Establishment Labs in the third quarter valued at $71,000. MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the fourth quarter valued at $146,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.